Resolute Science
San Diego
About Resolute Science
Resolute Science is advancing a pipeline of first-in-class, tumor-agnostic, targeted cytotoxic, and radiopharmaceutical therapeutics for solid tumors. With 16 in vivo studies completed showing profound single-agent anti-cancer efficacy, Resolute has the opportunity to transform the treatment of solid tumors. Resolute's MAC-TAC drug delivery platform enables the rapid development of synthetic drug conjugates designed to deliver a broad range of payloads deep into solid tumors. MAC-TACs are not restricted to tumor-specific receptors, so they can address multiple tumor types with a single drug while overcoming the resistance mechanisms associated with cancer-cell targeting therapeutics. Resolute's lead asset, RS-5, a MAC-TAC carrying an MMAE payload, is currently scheduled to enter clinical trials in Q1 2026.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $2.1M
- Last round: Series Unknown (Feb 2025)
- Website: resolutescience.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/resolute-science-97824 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.